47th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210361647 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS - The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. | 2021-11-25 |
20210361648 | NOVEL COMPOSITIONS AND METHODS - The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d | 2021-11-25 |
20210361649 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS - The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1. | 2021-11-25 |
20210361650 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS - The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions. | 2021-11-25 |
20210361651 | FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same. | 2021-11-25 |
20210361652 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders - The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity, in particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence. | 2021-11-25 |
20210361653 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS - This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided. | 2021-11-25 |
20210361654 | METHODS OF TREATING A VASCULAR LEAKAGE-ASSOCIATED DISEASE OR DISORDER - The present disclosure relates generally to treatment and diagnosis of diseases, disorders or conditions characterized by vascular leakage. More particularly, the present disclosure relates to methods for treating a vascular leakage-associated disease or disorder in a subject; for reducing vascular leakage in a subject; for reducing reactive oxygen species production in a subject; for inducing apoptosis of neutrophils in a subject; and for increasing survival of a subject having a vascular leakage-associated disease or disorder. The methods comprise administering a G9a and/or G9a-like protein (GLP) methyltransferase inhibitor to the subject. The present disclosure further relates to methods for developing a treatment plan for a subject with a vascular leakage-associated disease, disorder or condition, and for identifying a subject as a candidate for treatment of a vascular leakage-associated disease or disorder. The present disclosure relates to use of G9a and/or G9a-like protein (GLP) methyltransferase inhibitor in the treatment of vascular leakage-associated disease, disorder or condition. | 2021-11-25 |
20210361655 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 19 MUTATIONS - The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib. | 2021-11-25 |
20210361656 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. | 2021-11-25 |
20210361657 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) - Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor. | 2021-11-25 |
20210361658 | DEUTERATED RUC-4 - Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods. | 2021-11-25 |
20210361659 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2021-11-25 |
20210361660 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS - Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purinergic receptor antagonist and/or adenosine receptor antagonists. | 2021-11-25 |
20210361661 | SEMI-SOLID CAFFEINATED COMPOSITION AND METHODS OF MAKING AND USING THEREOF - A semi-solid composition comprising a gelling component in a sufficient amount to provide a cohesive gelled product, a caffeinated component comprising caffeine, wherein the caffeinated component is bitter, and a complexing component, wherein the complexing component is configured to reduce the bitterness of the caffeinated component by complexing with the caffeinated component. | 2021-11-25 |
20210361662 | TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS - The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R | 2021-11-25 |
20210361663 | Formulations of Antiviral Compounds - The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C vims NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations. | 2021-11-25 |
20210361664 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS - The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH). | 2021-11-25 |
20210361665 | TREATMENT OF SKIN LESIONS - The present invention is relates to a compound of formula (I), wherein X | 2021-11-25 |
20210361666 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE - Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent. | 2021-11-25 |
20210361667 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-11-25 |
20210361668 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity - A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. | 2021-11-25 |
20210361669 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS - The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A | 2021-11-25 |
20210361670 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID - Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration. | 2021-11-25 |
20210361671 | COMBINATION THERAPY CONTAINING IMMUNE BOOSTERS, DIGESTIVE ENZYMES AND INTERFERONS FOR CANCER TREATMENT - Methods and compositions for treating cancer in a patient in need thereof are provided. The methods comprise administering an interferon or an extract containing the interferon, an immune promoting agent and a digestive enzyme to the patient. The interferon can comprise withaferin A; the immune promoting agent can comprise vitamins and the digestive enzyme can comprise serratiopeptidase. | 2021-11-25 |
20210361672 | Method of Treating Ciliated Tissue Using CSA Micelles - The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a poloxamer, and a carrier. The combination of CSA compound and poloxamer allows higher concentrations of CSA compound to be used. Where such doses would normally disrupt ciliary function, the poloxamer prevents damage to ciliated tissue without inhibiting the antimicrobial effectiveness of the CSA compound. | 2021-11-25 |
20210361673 | COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS - The present disclosure is drawn to a methods of treating viral infections using androgen receptor agonists and compositions and dosages suitable therefor. | 2021-11-25 |
20210361674 | Treating Auto-Immune and Auto-Inflammatory Diseases - The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC. | 2021-11-25 |
20210361675 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease. | 2021-11-25 |
20210361676 | METHODS OF ADMINISTERING DEFLAZACORT THERAPY - The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor. | 2021-11-25 |
20210361677 | DOSING METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS - The invention provides methods and compositions for local administration of therapeutic agents to the rectum or colon, such as by enema. The methods and compositions are useful for treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. | 2021-11-25 |
20210361678 | SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP - Provided herein is a combination product comprising a Bcl-2 inhibitor, an anti-CD20 antibody and/or bendamustine or a combination product comprising a Bcl-2 inhibitor and CHOP, the combination product provides a use of the combination product for prevention and/or treatment of a disease (e.g., cancer, rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis). | 2021-11-25 |
20210361679 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND - Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone. | 2021-11-25 |
20210361680 | INOSITOL-BASED IMMUNOTHERAPIES - The present invention provides, inter alia, methods and compositions that are useful in the treatment of cancer. | 2021-11-25 |
20210361681 | METHOD FOR MANUFACTURING FUNCTIONAL MATERIAL INCLUDING PLASMALOGEN - A method for manufacturing a functional material that contains plasmalogen, the method including treating an animal tissue containing plasmalogen with protease, and extracting the animal tissue treated with protease with an extraction liquid containing ethanol. | 2021-11-25 |
20210361682 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use a therapeutic agents. | 2021-11-25 |
20210361683 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE CONTRACTURES - Disclosed herein are methods and compositions for the treatment of muscle contractures. In particular, the disclosed methods and compositions may be used to improve longitudinal muscle growth in individuals having muscle contractures, for example, muscle contractures resulting from cerebral palsy or brachial plexus injury. The methods and compositions may employ, for example, the administration of a therapeutic dose of a proteasome inhibitor. | 2021-11-25 |
20210361684 | USE OF MANNURONIC DIACID COMPOSITION IN TREATMENT OF PAIN - The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain. | 2021-11-25 |
20210361685 | TOBRAMYCIN COMPOUND CONJUGATES AND DERIVATIVE COMPOSITIONS - Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions. | 2021-11-25 |
20210361686 | METHODS OF TREATING EYE DISEASE WITH TOBRAMYCIN-RELATED COMPOSITIONS - Disclosed herein are compositions comprising tobramycin or a Disclosed herein are methods of treating conditions of the eye comprising delivering an effective amount of a composition comprising tobramycin or a tobramycin derivative complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both, or a tobramycin derivative that exhibits similar properties. In aspects, such compositions further comprise, or such methods further comprise associated administration of (e.g., as a combined product or via co-administration), one or more additional active agents capable of supporting the treatment of the indication for which the compounds of the invention are directed, such as additional antibacterial compounds, anti-inflammatory agents (e.g., steroids), and the like. | 2021-11-25 |
20210361687 | COMBINATION PRODUCTS OF TOBRAMYCIN COMPOUNDS AND DEXAMETHASONE COMPOUNDS - Disclosed herein are new compositions comprising (1) an antibacterial component comprising (a) a complex comprising (i) an active pharmaceutical ingredient (API) wherein the active pharmaceutical ingredient is tobramycin, a similar compound, or a derivative of either thereof and (ii) a complexing agent, or (b) a derivative of tobramycin or a similar compound comprising one or more conjugates/derivatizing groups, wherein the complexing agent or conjugate(s) cause a detectable increase in API permeation of corneal cells, retention in corneal cells, or both, as compared to the non-complexed or non-derivatized API, and (2) an effective amount of an anti-inflammatory agent, such as dexamethasone or another dexamethasone compound. This disclosure also describes new methods of using such compositions, producing such compositions, and the like. | 2021-11-25 |
20210361688 | SYSTEM, METHOD AND USE OF A CERTAIN MEDICATION FOR REDUCING VIRAL REPLICATION IN THE AIRWAYS MUCOSAE - A system, method, use, combination and kits useful in the administration of a certain medication for reducing viral replication of certain viruses during the early stage of transmission or as a prophylaxis when high risk of exposure to a virus is detected or predicted, administering efficiently a high local concentration of the certain medication while minimizing systemic exposure. Specifically it refers to a system, a method, a use, pharmaceutical combination and pharmaceutical kits of a certain nebulized medication to reduce viral replication. The development uses inhalers or nebulizers to deliver at least one certain medication directly into the upper and lower airways mucosae. | 2021-11-25 |
20210361689 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF - Gel formulations having antimicrobial activity are disclosed. Methods of using the gel formulation are further disclosed. | 2021-11-25 |
20210361690 | PHARMACEUTICAL COMPOSITION COMPRISING ADENOSINE DERIVATIVE FOR PREVENTION AND TREATMENT OF RETINAL DISEASE OR OPTIC NERVE DISEASE - The present invention relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases comprising the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease. | 2021-11-25 |
20210361691 | ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS - This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics. | 2021-11-25 |
20210361692 | Compositions and Methods for Treating Transthyretin (TTR) Mediated Amyloidosis - Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition. | 2021-11-25 |
20210361693 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS - Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs), antisense oligonucleotides, and small molecule inhibitors for therapeutic use. Additionally provided are methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products. | 2021-11-25 |
20210361694 | METHOD FOR PREVENTING OR TREATING CANCER USING SYT11 INHIBITOR - The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer. | 2021-11-25 |
20210361695 | P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION - Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome. | 2021-11-25 |
20210361696 | BIOLOGICALLY ACTIVE COMBINATORIAL POLYSACCHARIDE DERIVATIVES - The invention related to organic and bioorganic combinatorial chemistry, namely, to new combinatorial libraries of polysaccharide derivatives and supramolecular structures based on them, which, when used without separation into separate components, have high biological activity. | 2021-11-25 |
20210361697 | FORMULATIONS FOR TREATING ACID REFLUX COMPRISING SODIUM ALGINATE - The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders. | 2021-11-25 |
20210361698 | COMPOSITION FOR IMPROVING INTESTINAL BARRIER FUNCTION - An object of the present invention is to provide a composition for improving intestinal barrier function capable of improving intestinal barrier function. The present invention relates to a composition for improving intestinal barrier function, containing a flavan-3-ol polymer having a weight-average molecular weight of 4500 to 50000 as an active ingredient. | 2021-11-25 |
20210361699 | Novel Gold-Based Nanocrystals for Medical Treatments and Electrochemical Manufacturing Processes Therefor - The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. | 2021-11-25 |
20210361700 | NUTRITIONAL SUPPLEMENT TO COMBAT COVID-19 AND AID VACCINATION - The present invention provides compositions and methods for the treatment and prevention of COVID-19. The disclosed compositions comprise a combination of the natural compounds zinc, quercetin, vitamin E, and epigallocatechin gallate (EGCG), and are formulated for use in treating COVID-19, reducing the severity of disease, and enhancing the immune response to vaccination for COVID-19. | 2021-11-25 |
20210361701 | PENTAAZA MACROCYCLIC RING COMPLEXES FOR LOCAL DELIVERY - Aspects of the present disclosure relate to local delivery of pentaaza macrocyclic ring complexes to the intestines and methods of using the same. Certain disclosed dosage forms, including oral dosage forms suitable for local delivery and characterized by low systemic oral bioavailability, are therapeutically effective to relieve symptoms of inflammatory diseases of the lower gastrointestinal tract (e.g. small intestine, colon, and/or rectum) while minimizing systemic toxicity. | 2021-11-25 |
20210361702 | FLUORO SUBSTITUTED PORPHYRIN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME - Provided herein are fluoro-substituted porphyrin compounds, such as those having a structure represented by Formula (I), wherein R | 2021-11-25 |
20210361703 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF - The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid. | 2021-11-25 |
20210361704 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS - Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer. | 2021-11-25 |
20210361705 | REPROGRAMMING CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8aB AND CLASS 1 RESTRICTED T CELL RECEPTORS - Embodiments of the disclosure include methods and compositions related to improvements of T cell therapy. In particular embodiments, CD8+ T cell therapy is enhanced upon expression of transgenic E08αβ co-receptor in the CD8+ T cells. In certain embodiments, CD4+ T cells are rendered to have cytotoxic cell function for adoptive transfer upon expression of transgenic E08αβ co-receptor in the CD4+ T cells. In specific embodiments, TCR-expressing and E08αβ co-receptor-expressing CD4+ and CD8+ T cells are utilized in adoptive transfer. | 2021-11-25 |
20210361706 | COMBINATION OF NATURAL KILLER CELLS WITH CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER - Combined therapy of cancer (e.g., breast cancer) involving a cyclophosphamide compound and natural killer (NK) cells. Also provided herein are methods for inducing immune memory and/or reducing the risk of tumor recurrence using the combined therapy of a cyclophosphamide compound and NK cells. | 2021-11-25 |
20210361707 | METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS - The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32′ TCRy6+ T cells and to their clinical application. | 2021-11-25 |
20210361708 | METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS - The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32′ TCRy6+ T cells and to their clinical application. | 2021-11-25 |
20210361709 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-BCMA IMMUNOTHERAPY - Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed. | 2021-11-25 |
20210361710 | CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF - Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells. | 2021-11-25 |
20210361711 | CIML NK cells and Methods Therefor - Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost. | 2021-11-25 |
20210361712 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-11-25 |
20210361713 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-11-25 |
20210361714 | HYDROLYSED PROTEIN DEBITTERING COMPOSITION AND PRODUCT, PREPARATION, AND APPLICATION THEREOF - The present invention provides a composition for debittering hydrolyzed proteins and a product, preparation and use thereof. The composition comprises a short chain fatty acid, a medium chain fatty acid and a long chain fatty acid, wherein, based on total mass of the short chain fatty acid, the medium chain fatty acid and the long chain fatty acid which is 100%, the medium chain fatty acid is present in an amount of 0.2-4.7%, the long chain fatty acid is present in an amount of 95.1-99.4%, and the remaining is the short chain fatty acid. The present invention can effectively reduce the bitter taste of hydrolyzed proteins and is widely used. | 2021-11-25 |
20210361715 | USE OF EXOSOME DERIVED FROM MESENCHYMAL STEM CELLS CO-CULTURED WITH MELATONIN IN PREVENTION AND TREATMENT OF CHRONIC KIDNEY DISEASE - A new use of exosomes extracted from mesenchymal stem cells derived from a healthy individual co-cultured with melatonin or a culture solution thereof, for the treatment of chronic kidney disease is disclosed. A pharmaceutical composition containing the exosomes extracted from mesenchymal stem cells derived from a healthy individual co-cultured with melatonin or a culture solution thereof as an active ingredient and a method for preparing the pharmaceutical composition are disclosed. The exosomes promote the proliferation of mesenchymal stem cells derived from a chronic kidney disease patient or increase the survival rate of the patient. | 2021-11-25 |
20210361716 | METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS - The present invention relates to methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using cord blood tissue-derived mesenchymal stromal cells. | 2021-11-25 |
20210361717 | MESENCHYMAL CELL-DERIVED EXOSOMES TO TREAT NEUROLOGICAL DISORDERS - A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells. | 2021-11-25 |
20210361718 | METHODS AND COMPOSITIONS RELATED TO PLATELET RELEASATE AND PLATELET-RICH FIBRIN - The present disclosure provides compositions and methods comprising human platelet releasate (hPR), a xeno-free media supplement. The disclosure also relates to a cGMP process for the rapid, efficient and large-scale manufacturing of hPR that may be performed in less than 4 hours. The platelet releasate of the current disclosure prevents gelation of growth media alleviating the need for heparin or other anticoagulants. Mesenchymal stem cells expanded in the presence of platelet releasate have demonstrated superior expansion rates and potency compared to commercial supplements including platelet lysates. The releasate has therapeutic and medical applications. The disclosure also relates to compositions and methods related to platelet-rich fibrin. | 2021-11-25 |
20210361719 | METHODS AND MATERIALS FOR TREATING LUNG DISORDERS - This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided. | 2021-11-25 |
20210361720 | IMMUNOLOGICAL EXTRACT AND METHOD OF PRODUCTION - The present invention relates to a method of preparing an extract from edible bird's nest, a bird's nest extract and uses of the bird's nest extract. The method comprises preparing an edible bird's nest (EBN) mixture; and contacting the mixture with an extraction solution to bind a molecule in the mixture, wherein the extraction solution comprises at least one binding moiety selected from the group comprising an opsonin binding moiety, a complement protein binding moiety, a lectin binding moiety, a ficolin binding moiety, a collectin binding moiety, and a pentraxin binding moiety. | 2021-11-25 |
20210361721 | TREATMENT OF A CANCER BY MICROBIOME MODULATION - Methods are provided for identifying donors of fecal matter that can improve a subject's response to a checkpoint inhibitor in the treatment of cancer. Methods and compositions are also provided for using donated fecal matter in the treatment of cancer. | 2021-11-25 |
20210361722 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides a composition comprising a bacterial strain of the genus | 2021-11-25 |
20210361723 | COMPOSITION FOR PREVENTION AND TREATMENT OF ATOPIC DERMATITIS COMPRISING BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS LM1017 DERIVED FROM KOREAN INFANTS - This application claims the benefit under 35 USC 119(a) of Korean Patent Application No. 10-2017-0162218 filed on Nov. 30, 2016 in the Korean Intellectual Property Office, the entire disclosure of which is incorporated herein by reference for all purposes. | 2021-11-25 |
20210361724 | COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM CJLP475 STRAIN AND LACTOBACILLUS PLANTARUM CJLP243 STRAIN AND USE THEREOF - The present disclosure relates to a composition comprising a | 2021-11-25 |
20210361725 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES - Disclosed herein are compositions and methods for using human-derived | 2021-11-25 |
20210361726 | INHALED RESPIRATORY PROBIOTICS FOR LUNG DISEASES OF INFANCY, CHILDHOOD AND ADULTHOOD - The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of | 2021-11-25 |
20210361727 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONS - The present disclosure relates to compositions of bacteriophages, and use of the same for medical and non-medical applications, in particular treatment of | 2021-11-25 |
20210361728 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES AND IMMUNE CHECKPOINT THERAPY - A method of treating cancer in a subject that includes administering in situ to the cancer of the subject a therapeutically effective amount of a plant virus or plant virus-like particle in combination with administration of an immune checkpoint therapy to the subject. | 2021-11-25 |
20210361729 | Botanical Extract for Skin Care - A botanical extract for use in skin care, wherein the botanical extract is at least an extract from the testa of the seed of | 2021-11-25 |
20210361730 | PREPARATIONS CONTAINING ANTHOCYANINS FOR USE IN THE INFLUENCE OF CARDIOVASCULAR CONDITIONS - The present invention is related to preparations containing one or more anthocyanins for use in the prevention and treatment of cardiovascular diseases and reduction of arterial stiffness in a subject. | 2021-11-25 |
20210361731 | Oral Formulations Containing Enriched Polyphenolic Compounds together with a Form of Creatine, a Source of Choline and Trisodium Citrate - The oral supplements of the present invention utilize phenolic compounds in combination with creatine, choline, and trisodium citrate, wherein when taken together result in enhanced cellular permeation in comparison to cellular permeation in the absence of the other compounds of the combination leading to improved brain and/or physical functioning. | 2021-11-25 |
20210361732 | ROSEMARY EXTRACT COMPOSITION FOR MAINTAINING A HEALTHY BODY WEIGHT - A method of modulating body weight using a composition of rosemary extract having a predetermined amount of ursolic acid. | 2021-11-25 |
20210361733 | Prevention and Treatment of SARS-CoV-2 Infection by Mentha piperita and Flos chrysanthemi Extracts alone, and their Combination - Due to the SARS-CoV-2 pandemic, the development and screening of novel antiviral agents are urgently required. Herein, we developed herbal extracts with promising antiviral activity against SARS-CoV-2. Antiviral effects of | 2021-11-25 |
20210361734 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPY - The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy. | 2021-11-25 |
20210361735 | MINIGASTRIN DERIVATES, IN PARTICULAR FOR USE IN CCK2 RECEPTOR POSITIVE TUMOUR DIAGNOSIS AND/OR TREATMENT - It is therefore the objective of the present invention to provide minigastrin derivates which further improve the accumulation in CCK-2 receptor positive tumours by simultaneously very low accumulation in other organs, e.g. the kidneys. This objective is achieved according to the present invention by a minigastrin derivate having the formula: X-Z-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH | 2021-11-25 |
20210361736 | VISTA ANTAGONIST AND METHODS OF USE - The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist. | 2021-11-25 |
20210361737 | ANTI-INFECTIVE FORMULATIONS - The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections. | 2021-11-25 |
20210361738 | BACTERIOPHAGE-DERIVED RECOMBINANT PROTEIN HAVING ANTIMICROBIAL ACTIVITY AGAINST PATHOGENIC GRAM-NEGATIVE BACTERIA - The present invention relates to a bacteriophage-derived recombinant protein having antimicrobial activity against gram-negative bacteria, and the bacteriophage-derived recombinant protein LysSS exhibits killing activity to gram-negative bacteria and thus can prevent or treat infectious diseases caused by bacteria, and can be widely used in antibiotics, disinfectants, food additives, feed additives, and the like, wherein the LysSS uses peptidoglycan, which is a component of the cell wall of bacteria, as a substrate, and exhibits bacterial killing ability due to peptidoglycan degradation and the peptidoglycan exists only in bacteria and not in humans or animals. | 2021-11-25 |
20210361739 | C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSION - C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. | 2021-11-25 |
20210361740 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL AND OTHER DISORDERS - The present invention generally relates to methods for treating neurological and other disorders, including autoimmune disorders. One aspect of the invention relates to a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. In one embodiment the method includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88. | 2021-11-25 |
20210361741 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES - The present disclosure relates to nanoparticle formulations and methods of use for alpha connexin c-terminal peptides. Methods of making and methods of use, for example in the treatment of cancer, are also provided. | 2021-11-25 |
20210361742 | PEPTIDE THERAPEUTICS FOR THE TREATMENT OF CANCER AND USES THEREOF - The disclosure provides BI-1 modulating peptides and methods for treating cancer in a subject by administering an effective amount of a BI-1 modulating peptide. | 2021-11-25 |
20210361743 | METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) - Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions. | 2021-11-25 |
20210361744 | Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3) - The present disclosure provides, in part, a method of treating an autoimmune disease in a subject by reducing the number of pDCs through administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3). The disclosure also generally relates to methods of monitoring the effectiveness of therapy in subjects receiving DT-IL3 for treating an autoimmune disease, and methods of determining continuing treatment of subjects receiving DT-IL3 for treating an autoimmune disease. The disclosure also provides pharmaceutical compositions of DT-IL3 for use in such methods. | 2021-11-25 |
20210361745 | METHODS AND COMPOSITIONS FOR TREATING A FIBROTIC DISEASE - The present invention provides compositions and methods for the treatment of diseases and disorders. In some embodiments the compositions and methods involve administration of a microparticle, or composition thereof that includes an antifibrotic. | 2021-11-25 |
20210361746 | COMPOSITION AND METHOD FOR REDUCING HYPOGLYCEMIA EVENTS IN DIABETES TREATMENT - An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy. | 2021-11-25 |